Adapalene
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Adapalene: From Acne Vulgaris to Zinc, Elevated Plasma
One-Sentence Summary
Adapalene is a third-generation synthetic retinoid, widely used in dermatology for the treatment of acne vulgaris. The TxGNN model predicts it may be effective for zinc, elevated plasma (hyperzincaemia), with 0 clinical trials and 0 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acne vulgaris (standard clinical use; no UK marketing authorisation on record) |
| Predicted New Indication | Zinc, elevated plasma (hyperzincaemia) |
| TxGNN Prediction Score | 99.51% |
| Evidence Level | L5 |
| UK Market Status | Not authorised |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known clinical information, Adapalene is a third-generation synthetic retinoid with established efficacy in acne vulgaris. It is understood to act selectively on nuclear retinoic acid receptors (RAR-β and RAR-γ), modulating gene expression pathways involved in cellular differentiation, proliferation, and cutaneous inflammation.
The predicted new indication — elevated plasma zinc — pertains to disordered zinc homeostasis. A biologically plausible, albeit indirect, mechanistic link exists: zinc acts as a cofactor for retinol-binding proteins and several enzymes within the retinoid metabolic pathway. Conversely, retinoid receptor signalling may influence the expression of metallothioneins and zinc transporter proteins, which regulate systemic zinc distribution and plasma levels. This bidirectional interaction between retinoid and zinc biology forms the theoretical basis for the TxGNN knowledge graph association.
It is important to note, however, that the model’s high confidence score (99.51%) reflects structural relationships within the biomedical knowledge graph rather than direct experimental evidence. No supporting clinical, epidemiological, or mechanistic studies were identified. The scientific rationale, while not implausible, remains speculative, and this prediction should be treated with considerable caution at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: There is currently no clinical, observational, or mechanistic evidence supporting the use of Adapalene in the management of elevated plasma zinc; the prediction is model-generated only (Evidence Level L5), and the therapeutic plausibility of this indication requires substantial preliminary investigation before any forward steps can be justified.
To proceed, the following is needed:
- Retrieval and review of Adapalene’s full mechanism of action, with specific attention to any known effects on zinc metabolism, metallothionein expression, or zinc transporter regulation
- A targeted literature search for retinoid–zinc interaction studies in human subjects and in vitro models
- Clinical feasibility assessment: evaluation of whether elevated plasma zinc constitutes a viable, tractable therapeutic target for a retinoid-class agent, and whether an oral or systemic formulation of Adapalene would be required
- Clarification of UK regulatory status via the MHRA product licence database (PL registry), as Adapalene-containing topical products — such as Differin and Epiduo — are available in comparable markets
- Full safety data review from the SmPC and BNF prior to any further development activity, given the current absence of warning and contraindication data in this evidence pack
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.